Pharmacological Studies on Patients with Schizophrenia in Taiwan: A Compilation of Literature_

:::

詳目顯示

第 1 筆 / 總合 1 筆

/1頁

來源文獻資料
摘要
外文摘要
引文資料

題名：	Pharmacological Studies on Patients with Schizophrenia in Taiwan: A Compilation of Literature
書刊名：	Taiwanese Journal of Psychiatry
作者：	白雅美
作者(外文)：	Bai, Ya-mei
出版日期：	2012
卷期：	26:1
頁次：	頁6-18+66
主題關鍵詞：	抗精神病藥物；精神分裂症；臺灣；Antipsychotic drugs；Schizophrenia；Taiwan
原始連結：	連回原系統網址
相關次數：	被引用次數:期刊(3) 博士論文(0) 專書(0) 專書論文(0) 排除自我引用:3 共同引用:0 點閱:28

背景：台灣精神醫學界對精神分裂症之藥物學研究成果非常豐富，擬為近年來發表於國際期刊論文作分類摘要整理。方法：以「抗精神病藥物」、「精神分裂症」及「台灣」為關鍵字，於醫學期刊文獻資料庫（PubMed）搜尋台灣精神醫學界發表於國際期刊之論文。結果：研究論文依主題整理分為十類，包括療效研究、劑量調整、合併療法、藥物動力學、認知功能、治療預後、藥物副作用、藥物流行病學、藥物經濟學及藥物基因等類別。整體而言，除clozapine顯示有較佳療效外，其他抗精神病藥物療效相當，但副作用則有顯著差異。本土研究於藥物副作用之監測及處理、劑量調整、合併療法、藥物動力學等研究已有重要成果，可為臨床處理重要參考資料。療效及副作用的藥物基因學研究也相當豐富，為未來個人化治療提供重要資料，但仍需更多研究來驗證結果。相對而言在藥物認知功能、臨床預後及藥物經濟學的研究則較少。結論：台灣精神醫學界於精神分裂症之藥物學研究已有豐富研究成果，將可作為台灣精神分裂症藥物治療共識之基礎。

以文找文

Our Taiwan psychiatrists have actively studied pharmacotherapy in patients with schizophrenia. A compilation of lileration on this topic to gain an overview of pharmacological studies of schizophrenia in Taiwan is useful for psychiatrists in Taiwan to get quick and handy references. I identified Science Citation Index (SCI)-papers with the electronic search on the key words "antipsychotic," "schizophrenia," and "Taiwan" in PubMed (www.ncbi.nlm.nih.gov/pubmed). These articles were identified and annotated into 10 categories: (A) efficacy studies, including randomized double blind comparative studies, randomized single blind comparative studies, and open trials; (B) dose tuning; (C) augmentation therapy; (D) pharamcokinetic studies; (E) cognitive function; (F) prognosis; (G) side effects; (H) pharmaco-epidemiology; (I) pharmaco-economics; (J) pharmaco-genetics. Many Taiwan studies have offered empirical results of pharmacotherapy for schizophrenia in Taiwan. Besides clozapine, which is superior in efficacy, most studies showed comparable efficacy in treating schizophrenia among the different antipsychotic drugs, but with different side effect profiles. Many studies on monitoring and managing the side effects offered important references. The reports on dose tuning, augmentation with pharmacokinetic interaction, combination therapy or NMDA augmentation offered empirical evidence for clinical applications. The pharmaco-genetic studies showed evidence of genetic markers to predict efficacy and side effects in our Taiwan patients, trying to achieve the goal of individualized pharmacotherapy. But more studies are required to validate the results. The studies on cognition, clinical outcomes, pharmaco-economics are still limited in number. These studies have offered empirical results of pharmacotherapy for schizophrenia in Taiwan, and will be the basis for the development of the Taiwan consensus of pharmacological treatment for schizophrenia.

以文找文

期刊論文
1.	Chong, MY、Tan, CH、Fujii, S(2004)。Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change。Psychiatry Clin Neurosci，58，61-67。
2.	Sim, K.、Su, A.、Ungvari, G. S. et al.(2004)。Depot antipsychotic use in schizophrenia: an East Asian perspective。Hum Psychopharmacol，19，103-109。
3.	Sim, K.、Su, H. C.、Fujii, S. et al.(2009)。High-dose antipsychotic use in schizophrenia: a comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) studies。Br J Clin Pharmacol，67，110-117。
4.	Liu, C. Y.、Chiu, N. Y.、Wu, C. K.、Yuan, L. M.、Hsiao, M. C.、Liao, Oscar(2003)。Optimal Dose of Risperidone and Olanzapine for Patients with Schizophrenia in Taiwan。International Clinical Psychopharmacology，18，49-51。
5.	Lane, H. Y.、Chiu, W. C.、Chou, J. C.、Wu, S. T.、Su, M. H.、Chang, W. H.(2000)。Risperidone in Acutely Exacerbated Schizophrenia: Dosing Strategies and Plasma Levels。The Journal of Clinical Psychiatry，61，209-214。
6.	胡維恆、鄭平石、張文和、林式穀、藍先元、林信男(1997)。氯氮平之劑量與血中藥物濃度。臺灣醫學會雜誌，96(8)，599-605。延伸查詢
7.	劉絮愷、陳為堅、張景瑞、林信男(2000)。Effects of Atypical Neuroleptics on Sustained Attention Deficits in Schizophrenia: A Trial of Risperidone Versus Haloperidol。Neuropsychopharmacology，22(3)，311-319。
8.	Hong, CJ、Chen, JY、Chiu, HJ、Sim, CB(1997)。A double-blind comparative study of clozapine versus chlorproma-zine on Chinese patients with treatment-refractory schizophrenia。Clin Psychopharmacol，12，123-130。
9.	Hwang, TJ、Lin, SK、Lin, HN(2001)。Efficacy and safety of zotepine for the treatment of Taiwanese schizophrenic patients: a double-blind comparison with haloperidol。J Formos Med Assoc，100，811-816。
10.	Hwang, TJ、Lee, SM、Sun, HJ(2003)。Amisulpride versus risperidone in the treatment of schizophrenic patients: a double-blind pilot study in Taiwan。J Formos Med Assoc，102，30-36。
11.	Chan, H. Y.、Lin, W. W.、Lin, S. K.(2007)。Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial。J Clin Psychiatry，68，29-36。
12.	Bai, YM、Chen, TT、Wu, B(2006)。A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study。Pharmacopsychiatry，39，135-141。
13.	Hsu, WY、Huang, SS、Lee, BS、Chiu, NY(2010)。Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan。J Clin Psychopharmacol，30，230-234。
14.	Chiu, NY、Yang, YK、Chen, PS、Chang, CC、Lee, IH、Lee, JR(2003)。Olanzapine in Chinese treatment-resistant patients with schizophrenia: an open-label, prospective trial。Psychiatry Clin Neurosci，57，478-484。
15.	Lin, HC、Chong, MY、Lee, Y、Yeh, WC、Lin, PY(2009)。Switching of antipsychotics to aripiprazole in the treatment of schizophrenia。Chang Gung Med J，32，409-416。
16.	Lai, YC、Huang, MC、Chen, CH、Tsai, CJ、Pan, CH、Chiu, CC(2009)。Pharmacokinetics and efficacy of a direct switch from conventional depot to risperidone long-acting injection in Chinese patients with schizophrenic and schizoaffective disorders。Psychiatry Clin Neurosci，63，440-448。
17.	Lane, HY、Chang, YC、Chiu, CC、Lee, SH、Lin, CY、Chang, WH(2004)。Fine-tuning risperidone dosage for acutely exacerbated schizophrenia: clinical determinants。Psychopharmacology，172，393-399。
18.	Bai, YM、Chen, TT、Lin, WK(2007)。Pharmacokinetics study for hyperprolactinemia among schizophrenics switched from risperidone to risperidone long-acting injection。J Clin Psychopharmacol，27，306-308。
19.	Lane, HY、Chang, YC、Liu, YC、Chiu, CC、Tsai, GE(200511)。Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, doubleblind, placebo-controlled study。Arch Gen Psychiatry，62(11)，1196-1204。
20.	Lane, HY、Lin, CH、Huang, YJ、Liao, CH、Chang, YC、Tsai, GE(2010)。A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylgly-cine) and D-serine add-on treatment for schizophrenia。Int J Neuropsychopharmacol，13，451-460。
21.	Lane, HY、Liu, YC、Huang, CL(2008)。Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study。Biol Psychiatry，63，9-12。
22.	Lane, HY、Huang, CL、Wu, PL、Liu, YC、Chang, YC、Lin, PY(2006)。Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia。Biol Psychiatry，60，645-649。
23.	Huang, SS、Liao, YC、Hsieh, YY(2006)。Combination antipsychotic therapy in psychiatric outpatient clinics in Taiwan。Compr Psychiatry，47，421-425。
24.	Liu, HC、Chang, WH、Wei, FC、Lin, SK、Jann, MW(1996)。Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients。Ther Drug Monit，18，200-207。
25.	Lin, SK、Su, SF、Pan, CH(2006)。Higher plasma drug concentration in clozapine-treated schizophrenic patients with side effects of obsessive/compulsive symptoms。Ther Drug Monti，28，303-307。
26.	Lu, ML、Lane, HY、Chen, KP、Jann, MW、Su, MH、Chang, WH(2000)。Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients。J Clin Psychiatry，61，594-599。
27.	Chiu, CC、Lane, HY、Huang, MC(2004)。Dose-dependent alternations in the pharmacokinetics of olanzapine during coadministration of fluvoxamine in patients with schizophrenia。J Clin Pharmacol，44，1385-1390。
28.	Wu, TH、Chiu, CC、Shen, WW(2008)。Pharmacokinetics of olanzapine in Chinese male schizophrenic patients with various smoking behaviors。Prog Neuropsy-chopharmacol Biol Psychiatry，32，1889-1893。
29.	Lee, SM、Chou, YH、Li, MH、Wan, FJ、Yen, MH(2007)。Effects of antipsychotics on cognitive performance in drugnaive schizophrenic patients。Prog Neuropsycho-pharmacol Biol Psychiatry，31，1101-1107。
30.	Chen, PS、Yang, YK、Su, SF、Liao, YC、Chang, JW、Yeh, TL(2004)。Correlation between scores on Continuous Performance Test and plasma concentration for schizophrenic patients on risperidone。Psychiatry Clin Neurosci，58，168-172。
31.	Chang, YC、Lane, HY、Yang, KH、Huang, CL(2006)。Optimizing early prediction for antipsychotic response in schizophrenia。J Clin Psychopharmacol，26，554-559。
32.	Lin, CH、Chou, LS、Hsu, CY、Chen, YS、Lane, HY(2007)。Early prediction of Clinical response in schizophrenia patients receiving the atypical antipsychotic zotepine。J Clin Psychiatry，68，1522-1527。
33.	Lin, CH、Lin, SC、Chen, MC、Wang, SY(2006)。Comparison of time to rehospitalization among schizophrenic patients discharged on typical antipsychotics, clozapine or risperidone。J Chin Med Assoc，69，264-269。
34.	Li, CT、Su, TP、Chou, YH(2010)。Symptomatic resolution among Chinese patients with schizophrenia and associated factors。J Formos Med Assoc，109，378-388。
35.	Bai, YM、Lin, CC、Chen, JY、Lin, CY(1999)。Weight gain among patients on clozapine。Psychiatr Serv，50，704-705。
36.	Bai, YM、Lin, CC、Chen, JY、Lin CY, Su TP, Chou P: Association of initial antipsychotic response to clozapine and long-term weight gain. Am J Psychiatry(2006)。Association of initial antipsychotic response to clozapine and long-term weight gain。Am J Psychiatry，163，1276-1279。
37.	Bai, YM、Chen, JY、Chen, TT(2009)。Weight gain with clozapine: 8-year cohort naturalistic study among hospitalized Chinese schizophrenia patients。Schizophr Res，108，122-126。
38.	Wu, MK、Wang, CK、Bai, YM、Huang, CY、Lee, SD(2007)。Outcomes of obese, clozapine-treated inpatients with schizophrenia placed on a six-month diet and physical activity program。Psychiatr Serv，58，544-550。
39.	Bai, Y. M.、Lin, C. C.、Chen, J. Y.、Chen, T. T.、Su, T. P.、Chou, P.(2011)。Association of weight gain and metabolic syndrome in patients taking clozapine: an 8-year cohort study。J Clin Psychiatry，72，751-756。
40.	Bai, YM、Chen, JY、Yang, WS(2007)。Adiponectin as a potential biomarker for the metabolic syndrome in Chinese patients taking clozapine for schizophrenia。J Clin Psychiatry，68，1834-1839。
41.	Lu, ML、Lane, HY、Lin, SK、Chen, KP、Chang, WH(2004)。Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances。J Clin Psychiatry，65，766-771。
42.	Hsiao, CC、Ree, SC、Chiang, YL、Yeh, SS、Chen, CK(2004)。Obesity in schizophrenic outpatients receiving antipsychotics in Taiwan。Psychiatry Clin Neurosci，58，403-409。
43.	Huang, TL、Chen, JF(2005)。Serum lipid profiles and schizophrenia: effects of conventional or atypical antipsychotic drugs in Taiwan。Schizophr Res，80，55-59。
44.	Chiu, CC、Chen, KP、Liu, HC、Lu, ML(2006)。The early effect of olanzapine and risperidone on insulin secretion in atypical-naive schizophrenic patients。J Clin Psychopharmacol，26，504-507。
45.	Chiu, CC、Chen, CH、Chen, BY、Yu, SH、Lu, ML(2010)。The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine。Prog Neuropsychopharmacol Biol Psychiatry，34，866-870。
46.	Bai, YM、Chen, TT、Yang, WS(2009)。Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study。Schizophr Res，111，1-8。
47.	Lin, CC、Bai, YM、Chen, JY(2010)。Easy and low-cost identification of metabolic syndrome in patients treated with second-generation antipsychotics: artificial neural network and logistic regression models。J Clin Psychiatry，71，225-234。
48.	Chen, CK、Chen, YC、Huang, YS(2009)。Effects of a 10-week weight control program on obese patients with schizophrenia or schizoaffective disorder: a 12-month follow up。Psychiatry Clin Neurosci，63，17-22。
49.	Lin. C. C.、Bai. Y. M.、Wang. Y. C. et al.(2009)。Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics。J Clin Psychopharmacol，29，529-536。
50.	Chen, C. H.、Chiu, C. C.、Huang, M. C.、Wu, T. H.、Liu, H. C.、Lu, M. L.(2008)。Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine。Prog Neuropsychopharmacol Biol Psychiatry，32，925-931。
51.	Bai, YM、Yu, SC、Lin, CC(2003)。Risperidone for severe tardive dyskinesia: a 12-week randomized, doubleblind, placebo-controlled study。J Clin Psychiatry，64，1342-1348。
52.	Chen, JY、Bai, YM、Pyng, LY、Lin, CC(2001)。Risperidone for tardive dyskinesia。Am J Psychiatry，158，1931-1932。
53.	Bai YM, Yu SC, Chen JY, Lin CY, Chou P, Lin CC(2005)。Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study。Int Clin Psychopharmacol，20，79-85。
54.	Chan, HY、Chiang, SC、Chang, CJ(2010)。A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia。J Clin Psychiatry，71，1226-1233。
55.	Lu, ML、Shen, WW、Chen, CH(2008)。Prog Neuropsychopharmacol Biol Psychiatry。Prog Neuropsychopharmacol Biol Psychiatry，32，1978-1981。
56.	Bai, YM、Lin, CC、Chen, JY、Liu, WC(2001)。Therapeutic effect of pirenzepine for clozapine-induced hypersalivation: a randomized, double-blind, placebo-controlled, cross-over study。J Clin Psychopharmacol，21，608-611。
57.	Liang, C. S.、Ho, P. S.、Shen, L. J.、Lee, W. K.、Yang, F. W.、Chiang, K. T.(2010)。Comparison of the efficacy and impact on cognition of glycopyrrolate and biperiden for clozapine-induced sialorrhea in schizophrenic patients: A randomized, double-blind, crossover study。Schizophrenia Research，119(1)，138-144。
58.	Sim, K、Su, A、Leong, JY(2004)。High dose antipsychotic use in schizophrenia: findings of the REAP (research on east Asia psychotropic prescriptions) study。Pharmacopsychiatry，37，175-179。
59.	Yang, SY、Kao Yang, YH、Chong, MY、Yang, YH、Chang, WH、Lai, CS(2007)。Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based study。Clin Pharmacol Ther，21，586-594。
60.	Chang, HC、Tang, CH、Tsai, SJ、Yen, FC、Su, KP(2009)。Long-acting injectable risperidone and hospital readmission: a mirror-image study using a national claimbased database in Taiwan。J Clin Psychiatry，70，141。
61.	Gau, SS、Chung, CH、Gau, CS(2008)。A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in taiwan。J Clin Psychopharmacol，28，271-278。
62.	Lee, IH、Chen, PS、Yang, YK(2008)。The functionality and economic costs of outpatients with schizophrenia in Taiwan。Psychiatry Res，158，306-315。
63.	Hong, CJ、Yu, YW、Lin, CH、Cheng, CY、Tsai, SJ(2001)。Association analysis for NMDA receptor subunit 2B (GRIN2B) genetic variants and psychopathology and clozapine response in schizophrenia。Psychiatr Genet，11，219-222。
64.	Tsai, SJ、Wang, YC、Yu Younger, WY、Lin, CH、Yang, KH、Hong, CJ(2001)。Association analysis of polymorphism in the promoter region of the alpha2a-adrenoceptor gene with schizophrenia and clozapine response。Schizophr Res，49，53-58。
65.	Tsai, SJ、Hong, CJ、Yu, YW(2000)。Association study of a functional serotonin transporter gene polymorphism with schizophrenia, psychopathology and clozapine response。Schizophr Res，44，177-181。
66.	Yu, YW、Tsai, SJ、Lin, CH、Hsu, CP、Yang, KH、Hong, CJ(1999)。Serotonin-6 receptor variant (C267T) and clinical response to clozapine。Neuroreport，10，1231-1233。
67.	Hong, CJ、Yu, YW、Lin, CH、Tsai, SJ(2003)。An association study of a brain-derived neurotrophic factor Val66Met polymorphism and clozapine response of schizophrenic patients。Neurosci Lett，349，206-208。
68.	Yu, YW、Tsai, SJ、Yang, KH、Lin, CH、Chen, MC、Hong, CJ(2001)。Evidence for an association between polymorphism in the serotonin-2A receptor variant (102T/C) and increment of N100 amplitude in schizophrenics treated with clozapine。Neuropsychobiology，43，79-82。
69.	Lane, HY、Liu, YC、Huang, CL(2008)。RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia。J Clin Psychopharmacol，28，64-68。
70.	Lane, HY、Hsu, SK、Liu, YC、Chang, YC、Huang, CH、Chang, WH(2005)。Dopamine D3 receptor Ser9Gly polymorphism and risperidone response。J Clin Psychopharmacol，25，6-11。
71.	Lane HY, Chang YC, Chiu CC, Chen ML, Hsieh MH, Chang WH(2002)。Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene。Am J Psychiatry，159，1593-1595。
72.	Lane, HY、Lee, CC、Chang, YC、Lu, CT、Huang, CH、Chang, WH(2004)。Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function.。Int J Neuropsychopharmacol，7，461-470。
73.	Lane, HY、Lin, CC、Huang, CH、Chang, YC、Hsu, SK、Chang, WH(2004)。Risperidone response and 5-HT6 receptor gene variance: genetic association analysis with adjustment for nongenetic confounders。Schizophr Res，67，63-70。
74.	Chen, SF、Shen, YC、Chen, CH(1438)。G/ T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients。Psychopharmacology，205，285-292。
75.	Chen, SF、Shen, YC、Chen, CH(2009)。Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors。Prog Neuropsychopharmacol Biol Psychiatry，33，470-474。
76.	Shen, YC、Chen, SF、Chen, CH(2009)。Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients。J Psychiatr Res，43，600-606。
77.	Hong, CJ、Chen, TT、Bai, YM、Liou, YJ、Tsai, SJ(2012)。Impact of apolipoprotein A5 (APOA5) polymorphisms on serum triglyceride levels in schizophrenic patients under long-term atypical antipsychotic treatment。World J Biol Psychiatry，13，22-29。
78.	Bai, YM、Chen, TT、Liou, YJ、Hong, CJ、Tsai, SJ(2011)。Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics。Schizophr Res，125，179-186。
79.	Liou, YJ、Bai, YM、Lin E(2012)。Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics。Pharmacogenomics J，12，54-61。
80.	Hong, CJ、Liou, YJ、Bai, YM、Chen, TT、Wang, YC、Tsai, SJ(2010)。Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under longterm atypical antipsychotic treatment。Pharmacogenet Genomics，20，359-366。
81.	Wang, YC、Bai, YM、Chen, JY、Lin, CC、Lai, IC、Liou, YJ(2005)。C > G genetic variation and clozapine-in-duced weight gain。J Neural Transm，112，1463-1468。
82.	Wang, YC、Bai, YM、Chen, JY、Lin, CC、Lai, IC、Liou, YJ(2005)。C825T polymorphism in the human G protein beta3 subunit gene is associated with long-term clozapine treatment-induced body weight change in the Chinese population。Pharmacogenet Genomics，15，743-748。
83.	Wang, YC、Bai, YM、Chen, JY、Lin, CC、Lai, IC、Liou, YJ(2010)。Genetic association between TNF-alpha -308 G>A polymorphism and longitudinal weight change during clozapine treatment。Hum Psychopharmacol，25，303-309。
84.	Hong, C J、Lin, CH、Yu, YW、Yang, KH、Tsai, SJ(2001)。Genetic variants of the serotonin system and weight change during clozapine treatment。Pharmacogenetics，11，265-268。
85.	Liu, YR、Loh, EW、Lan, TH(2010)。ADRA1A gene is associated with BMI in chronic schizophrenia patients exposed to antipsychotics。Pharmacogenomics .J，10，30-39。
86.	Lai, IC、Che,n ML、Wang, YC(2011)。Analysis of genetic variations in the human melatonin receptor (MTNR1A, MTNR1B) genes and antipsychotics-in- duced tardive dyskinesia in schizophrenia。World J Biol Psychiatry，12，143-148。
87.	Lai, IC、Mo, GH、Chen, ML(2011)。Analysis Of genetic variations in the dopamine D1 receptor (DRD1) gene and antipsychotics-induced tardive dyskinesia in schizophrenia。Eur J Clin Pharmacol，67，383-388。
88.	Liou, YJ、Chen, ML、Wang, YC(2009)。Analysis of genetic variations in the RGS9 gene and antipsychotic-induced tardive dyskinesia in schizophrenia。Am J Med Genet B Neuropsychiatr Genet，150B，239-242。
89.	Liou, YJ、Wang, YC、Chen, JY(2008)。The coding-synonymous polymorphism rsl045280 (Ser280Ser) in beta-arrestin 2 (ARRB2) gene is associated with tardive dyskinesia in Chinese patients with schizophrenia。Eur J Neurol，15，1406-1408。
90.	Liou, YJ、Chen, ML、Wang, YC(2009)。Analysis of genetic variations in the human Par-4 (PAWR) gene and tardive dyskinesia in schizophrenia。Am J Med Genet B Neuropsychiatr Genet，150B，439-440。
91.	Mo, GH、Lai, IC、Wang, YC(2007)。Support for an association of the C939T polymorphism in the human DRD2 gene with tardive dyskinesia in schizophrenia。Schizophr Res，97，302-304。
92.	Liou, YJ、Lai, IC、Liao, DL(2006)。The human dopamine receptor D2 (DRD2) gene is associated with tardive dyskinesia in patients with schizophrenia。Schizophr Res，86，323-325。
93.	Liou, YJ、Lai, IC、Lin, MW(2006)。Haplotype analysis of endothelial nitric oxide synthase (NOS3) genetic variants and tardive dyskinesia in patients with schizophrenia。Pharmacogenet Genomics，16，151-157。
94.	Liou, YJ、Lai, IC、Wang, YC(2006)。Genetic analysis of the human ENTH (Epsin 4) gene and schizophrenia。Schizophr Res，84，236-243。
95.	Liou, YJ、Wang, YC、Lin, CC(2005)。Association analysis of NAD(P)Hratioquinone oxidoreductase (NQOl) Prol87Ser genetic polymorphism and tardive dyskinesia in patients with schizophrenia in Taiwan。Int J Neuropsychopharmacol，8，483-486。
96.	Liou, YJ、Wang, YC、Bai, YM(2004)。Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients。Neuropsychobiology，49，167-173。
97.	Liou, YJ、Liao, DL、Chen, JY(2004)。Association analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in Chinese schizophrenic patients。Neuromolecular Med，5，243-251。
98.	Wang, YC、Liou, YJ、Liao, DL(2004)。Association analysis of a neural nitric oxide synthase gene polymorphism and antipsychotics-induced tardive dyskinesia in Chinese schizophrenic patients。J Neural Transm，111，623-629。

推文
推薦
引用網址
引用嵌入語法
轉寄

top

:::

相關期刊
相關論文
相關專書
相關著作
熱門點閱

1.	Prevalence of Antipsychotic Drugs Related to Constipation in Patients with Schizophrenia
2.	Clinical Trials in Psychiatry: Focusing on Antipsychotic Development
3.	Research on Asian Prescription Patterns (REAP): Focusing on Data from Japan
4.	International Scientific Productivity on Second-generation Antipsychotic Drugs in Taiwan: A Bibliometric Study
5.	使用抗精神病藥物之精神分裂症及分裂情感性疾患門診病患之性功能障礙盛行率之實證評估
6.	The Barriers behind the Laws for the Rights to Employment for a Patient with Schizophrenia in Taiwan
7.	抗精神病藥物之發展沿革及最新趨勢
8.	精神分裂症治療之選藥原則
9.	精神分裂症
10.	抗精神病藥物之最近發展
11.	影響精神分裂症急性住院患者藥費之因素

無相關博士論文

無相關書籍

無相關著作

無相關點閱

QR Code

臺灣人文及社會科學引文索引資料庫系統

詳目顯示

臺灣人文及社會科學引文索引資料庫